Marathon Capital Management’s ADMA Biologics ADMA Stock Holding History

Marathon Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.62M	Sell	361,308 -171,045	-32%	-$1.58M	0.74%	41
2026 Q2	$4.46M	Sell	532,353 -95,035	-15%	-$866K	0.9%	37
2026 Q1	$5.65M	Buy	627,388 +162,073	+35%	+$2.56M	1.27%	25
2025 Q4	$8.49M	Sell	465,315 -1,255	-0.3%	-$21.2K	1.83%	14
2025 Q3	$6.84M	Buy	466,570 +182,880	+64%	+$3.13M	1.57%	18
2025 Q2	$5.17M	Buy	283,690 +128,570	+83%	+$2.62M	1.32%	22
2025 Q1	$3.08M	Buy	+155,120	New	+$2.68M	0.82%	37

Other funds holding ADMA

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

City Center Advisors LLC Troy, Michigan $131M AUM 24.02% 1-Year Est. Return

Kings Path Partners Sugar Land, Texas $380M AUM 12.42% 1-Year Est. Return

Marathon Capital Management's ADMA Position: Q3 2026 in Review

Marathon Capital Management reduced its ADMA Biologics (ADMA) stake by 32% in Q3 2026, selling an estimated $1.58M and leaving 361,308 shares worth $3.62M. The position accounts for 0.74% of the portfolio, ranked #41.

Marathon Capital Management first reported a position in ADMA in Q1 2025 and has held it in 7 quarters since. The position peaked at $8.49M in Q4 2025. 58 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

Marathon Capital Management held 361,308 shares of ADMA Biologics worth $3.62M as of Q3 2026.
Marathon Capital Management sold 171,045 ADMA Biologics shares in Q3 2026, an estimated $1.58M.
ADMA Biologics made up 0.74% of Marathon Capital Management's portfolio in Q3 2026, its #41 holding.
Marathon Capital Management first reported a position in ADMA Biologics in Q1 2025 and has held it in 7 quarters since.
Marathon Capital Management's ADMA Biologics position peaked at $8.49M in Q4 2025.
58 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Marathon Capital Management's 13F filing for Q3 2026, filed 23 Oct 2026.